Concepedia

Publication | Open Access

Upfront molecular targeted therapy for the treatment of BRAF-mutant pediatric high-grade glioma

56

Citations

42

References

2022

Year

Abstract

Upfront targeted therapy for patients with BRAF-mutant pHGG is feasible and effective, with superior clinical outcomes compared to historical data. This promising treatment paradigm is currently being evaluated prospectively in the Children's Oncology Group ACNS1723 clinical trial.

References

YearCitations

Page 1